Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2007-12-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 50
- Registration Number
- NCT00292422
- Locations
- 🇺🇸
Fiechtner Research Inc., Lansing, Michigan, United States
🇺🇸Arthritis Consultants Inc., St. Louis, Missouri, United States
🇺🇸The Arthritis Group, Philadelphia, Pennsylvania, United States
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 300
- Registration Number
- NCT00288990
- Locations
- 🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸Physicians Resource Network, Cullman, Alabama, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2000
- Registration Number
- NCT00280956
- Locations
- 🇺🇸
Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in, San Diego, California, United States
Open-Label Natalizumab Safety Extension Study
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1615
- Registration Number
- NCT00276172
- Locations
- 🇺🇸
Performed at only C-1801, C-1802, and C-1803 sites globally. No general public enrollment. Biogen Idec is located in, Cambridge, Massachusetts, United States
Safety and Tolerability of Repeat Courses of IM Alefacept
- Conditions
- Chronic Plaque Psoriasis
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT00233662
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Clinical Research Specialists, Inc., Santa Monica, California, United States
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
- Conditions
- Prenatal Exposure Delayed EffectsMultiple SclerosisPregnancy
- Interventions
- Drug: BG9418 (interferon beta-1a)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 329
- Registration Number
- NCT00168714
- Locations
- 🇺🇸
Kendle, Wilmington, North Carolina, United States
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
- Conditions
- Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 150
- Registration Number
- NCT00168740
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope Natioal Medical Center, Duarte, California, United States
🇺🇸Scripps Memorial Hospital, La Jolla, California, United States
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 345
- Registration Number
- NCT00168766
- Locations
- 🇧🇪
CUB Hôpital Erasme, Bruxelles, Belgium
🇩🇰Coordinating Research Site, Copenhagen, Denmark
🇩🇰Rigshospitalet, Skleroseklinikken, Denmark
Efficacy and Safety of BG00012 in MS
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 260
- Registration Number
- NCT00168701
- Locations
- 🇨🇿
Faculty Hospital St. Anne, Bmo, Czechia
🇨🇿Faculty Hospital, Hradec Kralove, Czechia
🇨🇿Hospital of Pardubice, Pardupice, Czechia
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma, Low-GradeLymphoma, Non-Hodgkin
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT00168727
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸North County Oncology, Oceanside, California, United States
🇺🇸Medical Specialists of Fairfield, Fairfield, Connecticut, United States